Danaher Corporation

Danaher Corporation is an American global science and technology company that operates across three segments — Biotechnology, Life Sciences, and Diagnostics — serving pharmaceutical, biopharmaceutical, academic, clinical, and applied markets in roughly 50 countries, generating $24.6 billion in revenue in fiscal 2025. The company operates through more than 15 operating companies including Cytiva, Pall, Beckman Coulter Life Sciences, SCIEX, Leica Microsystems, Aldevron, Abcam, IDT, Beckman Coulter Diagnostics, Cepheid, Radiometer, and Leica Biosystems — brands that collectively hold leading positions in bioprocessing, laboratory instruments, and clinical diagnostics.

This is a story about a conglomerate that reinvented itself from a diversified industrial holding company into a life sciences and diagnostics powerhouse, powered by an obsessive operating philosophy called the Danaher Business System. Along the way it spun off its water-quality and product-identification businesses as Veralto in 2023, sharpening the portfolio around human health, and added the $9.9 billion acquisition of Masimo in June 2026 to extend its Diagnostics reach into acute-care patient monitoring. The current file is shaped by three cross-currents: a nascent recovery in bioprocessing equipment investment after two years of under-spending, a margin recovery story in Life Sciences that has been slower to arrive than bulls expected, and a Diagnostics franchise that keeps growing through China volume-based procurement headwinds.

This file turns on a single question: whether the organic growth recovery that management has guided toward materialises before the market's patience — and the multiple — runs out.